Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
73.78
-0.56 (-0.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
33
34
Next >
FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings
January 26, 2022
The
Via
Benzinga
Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way
January 25, 2022
Sierra Oncology spent just $3 million up front to acquire momelotinib.
Via
Investor's Business Daily
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
January 24, 2022
Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their...
Via
Benzinga
A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge
January 24, 2022
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled 450 points in the previous session. Investors are awaiting earnings results...
Via
Benzinga
FDA Approves Gilead's Remdesivir For Non-Hospitalized COVID-19 Patients At High Risk For Disease Progression
January 24, 2022
The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) for non-hospitalized adult and adolescent patients at high risk of progression to...
Via
Benzinga
Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field
January 20, 2022
Key Takeaways Everest has signed a global licensing deal for an anti-viral Covid treatment being developed by Singapore’s Experimental Drug Development Centre Similar oral...
Via
Benzinga
Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs
January 19, 2022
Gilead Sciences Inc (NASDAQ: GILD) said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV...
Via
Benzinga
Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US
January 18, 2022
Gilead Sciences Inc (NASDAQ: GILD) recently notified the FDA of its decision to voluntarily withdraw the use of Zydelig for two types of blood cancer, including...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
January 12, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...
Via
Benzinga
7 Safe Stocks for Your Retirement
January 07, 2022
In a dynamic market like the one we're in now, it's important to buy safe stocks that will build your nest egg in the years to come.
Via
InvestorPlace
What 5 Analyst Ratings Have To Say About Gilead Sciences
January 06, 2022
Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings wi...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
January 06, 2022
Upgrades For Canada Goose Holdings Inc (NYSE:
Via
Benzinga
10 Biggest Price Target Changes For Thursday
January 06, 2022
JP Morgan raised the price target for RPM International Inc. (NYSE:
Via
Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
January 06, 2022
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich
Via
InvestorPlace
Dogs of Major Indices
December 30, 2021
As we approach the end of 2021, we take a look at the ten Dow stocks that would currently make up the Dogs of the Dow for 2022.
Via
Talk Markets
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
December 29, 2021
Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The...
Via
Benzinga
NRXP Stock Alert: What Is Going on With NRx Pharmaceuticals Today?
December 29, 2021
NRx is seeking breakthrough designation for its treatment based on new, favorable data on the drug. NRXP stock is climbing on the news.
Via
InvestorPlace
Pfizer's CEO Shows You How To Get 'Impossible' Tasks Done Fast
December 29, 2021
Scientists told the Pfizer CEO they could create a vaccine in 18 months. But Albert Bourla knew they could work even faster.
Via
Investor's Business Daily
Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S.
December 28, 2021
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
Best Stocks For Wheel Strategy Trades: Use These In 2022
December 26, 2021
Blue chips companies, high dividend stocks, REITs, and low beta ETFs work well when employing the wheel strategy.
Via
Talk Markets
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19
December 23, 2021
Gilead Sciences Inc (NASDAQ: GILD) announced full results from a Phase 3 study of a three-day course of Veklury (remdesivir) non-hospitalized COVID-19 patients at...
Via
Benzinga
Price To Earnings Ratio Insights For Gilead Sciences
December 22, 2021
In the current market session, Gilead Sciences Inc. (NASDAQ:GILD) is trading at $70.76, after a 1.50% decrease. However, over the past month, the stock went up by 0.98%,...
Via
Benzinga
FDA Slaps Clinical Hold On Gilead's Injectable Lenacapavir In HIV Trials
December 22, 2021
The FDA has placed a clinical hold on Gilead Sciences Inc's (NASDAQ: GILD) injectable lenacapavir in borosilicate vials in all ongoing clinical studies...
Via
Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
December 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With...
Via
Benzinga
European Commission Expands Use Of Remdesivir In COVID-19 Patients Not On Supplemental Oxygen
December 21, 2021
The European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Gilead Sciences Inc's (NASDAQ: GILD) Veklury (...
Via
Benzinga
EMA Might Not Decide On Merck's COVID-91 Oral Antiviral Before Christmas: Reuters
December 17, 2021
The EU drug regulator might not decide whether to approve Merck & Co Inc's (NYSE: MRK) molnupiravir, COVID-19 antiviral until after Christmas, a source with...
Via
Benzinga
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
December 14, 2021
Kite Pharma, a Gilead Science Inc company (NASDAQ: GILD), churned out more data for its CAR-T Yescarta in first-line lymphoma patients. The Company...
Via
Benzinga
Gilead's Kite Unveils More Data On Yescarta In Second-Line Lymphoma Patients
December 13, 2021
Kite Pharma, a Gilead Science Inc's Company (NASDAQ: GILD), announced primary analysis results from the ZUMA-7 Phase 3 trial of Yescarta (axicabtagene...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
December 09, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:
Via
Benzinga
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.